J&J/Medtronic stent litigation
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will seek Supreme Court review after petition from both parties for rehearing - and rehearing en banc - of Palmaz stent patent suit is denied by U.S. Court of Appeals for the Federal Circuit Sept. 29. The court sided with J&J in August, and remanded the case back to its original Delaware district court (1"The Gray Sheet" Aug. 18, 2003, p. 4)...
You may also be interested in...
Litigation In Brief
J&J/Medtronic stent litigation: Supreme Court declines to review ruling awarding Johnson & Johnson/Cordis $271 mil. for infringement of stent patents, including those related to its Palmaz-Schatz('762), denying a writ of certiorari in the case. The U.S. Court of Appeals for the Federal Circuit had denied a rehearing in September 2003 after siding with J&J last August and remanded the case back to its original Wilmington, Del. district court (1"The Gray Sheet" Oct. 6, 2003, In Brief). Medtronic notes that the stents at issue are obsolete...
J&J V. Medtronic: Palmaz-Schatz Infringement Claims Sway Appeals Panel
Medtronic's invocation of the doctrine of equivalents as a legal defense against Johnson & Johnson/Cordis failed to convince a three-judge appeals court panel that Medtronic had not infringed key Cordis patents
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.